<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00964951</url>
  </required_header>
  <id_info>
    <org_study_id>09-0060</org_study_id>
    <secondary_id>N01AI80007C</secondary_id>
    <nct_id>NCT00964951</nct_id>
  </id_info>
  <brief_title>CSL H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations</brief_title>
  <official_title>A Phase II Study in Healthy Adult and Elderly Populations to Assess the Safety and Immunogenicity of a CSL H1N1 Influenza Vaccine Administered at Different Dose Levels Given With and Without GlaxoSmithKline AS03 Adjuvant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see how the body reacts to different strengths of the H1N1&#xD;
      flu shot when it is given with or without an &quot;adjuvant.&quot; An adjuvant is a substance that may&#xD;
      cause the body to produce more antibodies when it is given with a vaccine. This study will&#xD;
      also compare how age affects the body's response to the H1N1 flu shot. In this study, 3&#xD;
      strengths of the H1N1 flu shot will be tested combined with an adjuvant. In addition, 2&#xD;
      strengths of the H1N1 flu shot will be tested without adjuvant. Two H1N1 flu shots of the&#xD;
      same strength, with or without adjuvant, will be given about 3 weeks apart. Participants will&#xD;
      include up to 800 healthy adults, approximately 500 individuals ages 18-64 and 250&#xD;
      individuals greater than or equal to age 65. Study procedures include: physical exam, blood&#xD;
      samples, completing a memory aid to record vaccine side effects, medications and daily oral&#xD;
      temperature. Participants will be involved in study related procedures for up to 13 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently, a novel swine-origin influenza A/H1N1 virus was identified as a significant cause&#xD;
      of febrile respiratory illnesses in Mexico and the United States. It rapidly spread prompting&#xD;
      the World Health Organization to declare a pandemic. Data from several cohorts in different&#xD;
      age groups that received licensed trivalent seasonal influenza vaccines suggest that these&#xD;
      vaccines are unlikely to provide protection against the new virus. These data indicate the&#xD;
      need to develop vaccines against the new H1N1 strain and suggest that different vaccine&#xD;
      strategies (e.g., number of doses, need for adjuvant) may be appropriate for persons in&#xD;
      different age groups. Based on clinical data from the clinical trials with vaccines&#xD;
      containing novel influenza A antigens, a higher dosage, or multiple doses of a novel antigen&#xD;
      may be necessary to generate potentially protective antibody responses. Alternatively,&#xD;
      inactivated influenza H1N1 vaccines administered with adjuvants, such as AS03, may confer&#xD;
      protection to a maximal number of vaccine recipients. This protocol will explore antibody&#xD;
      responses following vaccination with an inactivated influenza H1N1 virus vaccine at 3&#xD;
      different dose levels combined with AS03 adjuvant and at 2 different dose levels administered&#xD;
      without adjuvant. This study will assess the immune response following a single dose of&#xD;
      vaccine with or without AS03 adjuvant, to assess whether individuals have any pre-existing&#xD;
      'prime' immunity, such that the initial H1N1 vaccination serves as a boost, thus conferring a&#xD;
      more rapid time to protection with the need for fewer doses. Antibody responses will be&#xD;
      assessed 8 days after each dose to evaluate the development of an anamnestic response. In&#xD;
      addition, antibody responses will be assessed 21 days after each dose. The primary objectives&#xD;
      are: safety, to assess the safety of inactivated H1N1 vaccine when administered at 3.75, 7.5&#xD;
      or 15 mcg combined with AS03 adjuvant and at 7.5 or 15 mcg administered without adjuvant; and&#xD;
      immunogenicity, to assess the antibody response at Day 21 following a single dose of&#xD;
      inactivated H1N1 vaccine when administered at 3.75, 7.5 or 15 mcg combined with AS03 adjuvant&#xD;
      and at 7.5 or 15 mcg administered without adjuvant, stratified by age of recipient. The&#xD;
      secondary objective is immunogenicity, to assess the antibody response following 2 doses of&#xD;
      inactivated H1N1 vaccine when administered at 3.75, 7.5 or 15 mcg combined with AS03 adjuvant&#xD;
      and at 7.5 or 15 mcg administered without adjuvant, stratified by age of recipient.&#xD;
      Participants will include up to 800 healthy adults who have no history of novel influenza&#xD;
      H1N1 2009 infection or novel influenza H1N1 2009 vaccination. This is a randomized,&#xD;
      double-blinded, Phase II study. Subjects will be randomized into 5 groups, stratified by age&#xD;
      (150 subjects per dose group with 100 subjects in the 18-64 years of age stratum and 50&#xD;
      subjects in the greater than or equal to 65 years of age stratum), to receive intramuscular&#xD;
      inactivated influenza H1N1 vaccine at 3.75, 7.5 or 15 mcg combined with AS03 adjuvant (Groups&#xD;
      1, 2, and 3, respectively) or at 7.5 or 15 mcg without adjuvant (Groups 4 and 5,&#xD;
      respectively). The vaccine, with and without adjuvant, will be administered at Days 0 and 21.&#xD;
      Following immunization, safety will be measured by assessment of adverse events (AEs) through&#xD;
      21 days following the last vaccination (Day 42 for those receiving both doses and Day 21 for&#xD;
      those who do not receive the second dose), serious adverse events (SAEs) and new-onset&#xD;
      chronic medical conditions through 12 months post final vaccination (Day 365 after second&#xD;
      vaccination), and reactogenicity to the vaccine for 8 days following each vaccination (Day&#xD;
      0-7). Immunogenicity testing will include hemagglutination inhibition assay (HAI) and&#xD;
      neutralizing antibody testing on serum obtained prior to each vaccination, 8-10 days after&#xD;
      each vaccination, 21 days (Day 42), 6 months (Day 201) and 12 months (Day 386) following the&#xD;
      second vaccination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <completion_date type="Anticipated">November 2010</completion_date>
  <primary_completion_date type="Anticipated">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: occurrence of safety laboratory adverse events (AEs).</measure>
    <time_frame>Days 0, 8-10, 21 and 29.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: occurrence of vaccine-associated serious adverse events (SAEs).</measure>
    <time_frame>Throughout the course of the study.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity: proportion of subjects, stratified by age, achieving a serum HAI antibody titer of 1:40 or greater, against influenza H1N1 2009 virus at Day 21 following a single dose of H1N1 vaccine combined with or without AS03 adjuvant.</measure>
    <time_frame>Day 21.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity: proportion of subjects, stratified by age, with 4-fold or greater hemagglutination inhibition (HAI) antibody titer increases against influenza H1N1 2009 virus at Day 21 following a single dose of H1N1 vaccine with or without AS03.</measure>
    <time_frame>Day 21.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: occurrence of solicited local and systemic adverse events (AEs).</measure>
    <time_frame>Within 8 days post vaccination (Day 0-7).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: proportion of subjects, stratified by age, achieving a serum HAI antibody titer of 1:40 or greater against influenza H1N1 2009 virus following 2 doses of H1N1 vaccine combined with or without AS03 adjuvant.</measure>
    <time_frame>Day 29, Day 42, 6 months (Day 201) and 12 months (Day 386).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: proportion of subjects, stratified by age, with 4-fold or greater HAI antibody titer increases against influenza H1N1 2009 virus following 2 doses of H1N1 vaccine combined with or without AS03 adjuvant.</measure>
    <time_frame>Day 29, Day 42, 6 months (Day 201) and 12 months (Day 386).</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group 3: 15 mcg H1N1 vaccine + AS03 adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: 3.75 mcg H1N1 vaccine + AS03 adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: 7.5 mcg H1N1 vaccine unadjuvanted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: 7.5 mcg H1N1 vaccine + AS03 adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: 15 mcg H1N1 vaccine unadjuvanted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AS03</intervention_name>
    <description>AS03 adjuvant administered with 3.75, 7.5, or 15 mcg Inactivated H1N1 Vaccine.</description>
    <arm_group_label>Group 1: 3.75 mcg H1N1 vaccine + AS03 adjuvant</arm_group_label>
    <arm_group_label>Group 2: 7.5 mcg H1N1 vaccine + AS03 adjuvant</arm_group_label>
    <arm_group_label>Group 3: 15 mcg H1N1 vaccine + AS03 adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated H1N1 Vaccine</intervention_name>
    <description>Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.</description>
    <arm_group_label>Group 1: 3.75 mcg H1N1 vaccine + AS03 adjuvant</arm_group_label>
    <arm_group_label>Group 2: 7.5 mcg H1N1 vaccine + AS03 adjuvant</arm_group_label>
    <arm_group_label>Group 3: 15 mcg H1N1 vaccine + AS03 adjuvant</arm_group_label>
    <arm_group_label>Group 4: 7.5 mcg H1N1 vaccine unadjuvanted</arm_group_label>
    <arm_group_label>Group 5: 15 mcg H1N1 vaccine unadjuvanted</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are males or non-pregnant females age 18 and older, inclusive.&#xD;
&#xD;
          -  Women of child-bearing potential (not surgically sterile via tubal ligation, bilateral&#xD;
             oophorectomy or hysterectomy or who are not postmenopausal for greater than or equal&#xD;
             to 1 year) must agree to practice adequate contraception that may include, but is not&#xD;
             limited to, abstinence, monogamous relationship with vasectomized partner, barrier&#xD;
             methods such as condoms, diaphragms, spermicides, intrauterine devices, and licensed&#xD;
             hormonal methods during the study for at least 30 days following the last vaccination.&#xD;
&#xD;
          -  Are in good health, as determined by vital signs, medical history to ensure any&#xD;
             existing medical diagnoses or conditions are stable and not considered clinically&#xD;
             significant, and limited physical examination. A stable chronic medical condition is&#xD;
             defined as no change in prescription medication, dose, or frequency of medication in&#xD;
             the last 3 months and health outcomes of the specific disease are considered to be&#xD;
             within acceptable limits in the last 6 months. Any change that is due to change of&#xD;
             health care provider, insurance company etc, or that is done for financial reasons, as&#xD;
             long as in the same class of medication will not be considered a violation of this&#xD;
             inclusion criterion. Any change in prescription medication due to improvement of a&#xD;
             disease outcome will not be considered a violation of this inclusion criterion.&#xD;
&#xD;
          -  Have erythrocyte sedimentation rate (ESR) less than 30 mm per hour.&#xD;
&#xD;
          -  Are able to understand and comply with planned study procedures.&#xD;
&#xD;
          -  Provide written informed consent prior to initiation of any study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a known allergy to eggs or other components of the vaccine (including squalene&#xD;
             based adjuvants, thimerosal, neomycin, polymyxin, and chicken protein).&#xD;
&#xD;
          -  Have a positive urine or serum pregnancy test within 24 hours prior to vaccination if&#xD;
             female of childbearing potential or women who are breastfeeding.&#xD;
&#xD;
          -  Have immunosuppression as a result of an underlying illness or treatment, or use of&#xD;
             anticancer chemotherapy or radiation therapy (cytotoxic) within the preceding 36&#xD;
             months.&#xD;
&#xD;
          -  Have an active neoplastic disease or a history of any hematologic malignancy.&#xD;
&#xD;
          -  Have long term use of glucocorticoids including oral, parenteral or high-dose inhaled&#xD;
             steroids (&gt;800 micrograms (mcg)/day of beclomethasone dipropionate or equivalent)&#xD;
             within the preceding 6 months. (Nasal and topical steroids are allowed.)&#xD;
&#xD;
          -  Have a diagnosis of schizophrenia, bipolar disease, or other major psychiatric&#xD;
             diagnosis.&#xD;
&#xD;
          -  Have been hospitalized for psychiatric illness, history of suicide attempt, or&#xD;
             confinement for danger to self or others, within the past 10 years.&#xD;
&#xD;
          -  Are receiving psychiatric drugs (aripiprazole, clozapine, ziprasidone, haloperidol,&#xD;
             molindone, loxapine, thioridazine, thiothixene, pimozide, fluphenazine, risperidone,&#xD;
             mesoridazine, quetiapine, trifluoperazine, chlorprothixene, chlorpromazine,&#xD;
             perphenazine, trifluopromazine, olanzapine, carbamazepine, divalproex sodium, lithium&#xD;
             carbonate or lithium citrate). Subjects who are receiving a single antidepressant drug&#xD;
             and are stable for at least 3 months prior to enrollment, without de-compensating&#xD;
             symptoms will be allowed to be enrolled in the study.&#xD;
&#xD;
          -  Have a history of receiving immunoglobulin or other blood product within the 3 months&#xD;
             prior to vaccination in this study.&#xD;
&#xD;
          -  Received an experimental agent (vaccine, drug, biologic, device, blood product, or&#xD;
             medication) within 1 month prior to vaccination in this study or expect to receive an&#xD;
             experimental agent during this study (prior to the Day 386 clinic visit - 365 days&#xD;
             after the second vaccination).&#xD;
&#xD;
          -  Have received any live licensed vaccines within 4 weeks or inactivated licensed&#xD;
             vaccines within 2 weeks prior to vaccination in this study or plan receipt of such&#xD;
             vaccines within 21 days following the second vaccination. This is inclusive of&#xD;
             seasonal influenza vaccines.&#xD;
&#xD;
          -  Have an acute or chronic medical condition that, in the opinion of the investigator,&#xD;
             would render vaccination unsafe, or would interfere with the evaluation of responses.&#xD;
&#xD;
          -  Have a history of severe reactions following previous immunization with influenza&#xD;
             virus vaccines.&#xD;
&#xD;
          -  Have an acute illness, including an oral temperature greater than 100.4 degrees&#xD;
             Fahrenheit, within 3 days prior to vaccination.&#xD;
&#xD;
          -  Have any condition that would, in the opinion of the site investigator, place them at&#xD;
             an unacceptable risk of injury or render them unable to meet the requirements of the&#xD;
             protocol.&#xD;
&#xD;
          -  Participated in a novel influenza H1N1 2009 vaccine study in the past 2 years or have&#xD;
             a history of novel influenza H1N1 2009 infection prior to enrollment.&#xD;
&#xD;
          -  Have known active human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C&#xD;
             infection or autoimmune hepatitis.&#xD;
&#xD;
          -  Have a history of alcohol or drug abuse in the last 5 years.&#xD;
&#xD;
          -  Plan to travel outside of North America in the time between the first vaccination and&#xD;
             42 days following the first vaccination.&#xD;
&#xD;
          -  Have a history of Guillain-Barr√© Syndrome.&#xD;
&#xD;
          -  Have any condition that the investigator believes may interfere with successful&#xD;
             completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>August 20, 2009</study_first_submitted>
  <study_first_submitted_qc>August 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2009</study_first_posted>
  <last_update_submitted>October 11, 2018</last_update_submitted>
  <last_update_submitted_qc>October 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2018</last_update_posted>
  <responsible_party>
    <name_title>Robert Johnson</name_title>
    <organization>HHS/NIAID/DMID</organization>
  </responsible_party>
  <keyword>H1N1, influenza A viruses, vaccine, elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

